Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
EBITDA margins expand to 31.3%
Increases speed to market for drug developers working on nucleic acid therapeutics
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
India has taken the lead in recognising NAFLD as a major non-communicable disease
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Nearly 200 participants from 50 Unani Academia and Council participated
Revolutionary technology will further boost OneSource’s scientific services offerings
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Subscribe To Our Newsletter & Stay Updated
